Elizabeth M. Kudlacz

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

Paul S. Changelian, Mark E. Flanagan, Douglas J. Ball et al. · Science · 2003 · 670 citations · Full text

Medicine, Immunology, Pharmacology +17

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

Dafna D. Gladman, William F. C. Rigby, Valderílio Feijó Azevedo et al. · New England Journal of Medicine · 2017 · 508 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection

Mark E. Flanagan, Todd A. Blumenkopf, William H. Brissette et al. · Journal of Medicinal Chemistry · 2010 · 335 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year

Flavio Vincenti, Stéphan Busque, Philip J. O’Connell et al. · American Journal of Transplantation · 2012 · 162 citations · Full text

Medicine, Nephrology, Pharmacology +17

The Novel JAK-3 Inhibitor CP-690550 Is a Potent Immunosuppressive Agent in Various Murine Models

Elizabeth M. Kudlacz, Bret D. Perry, Perry S. Sawyer et al. · American Journal of Transplantation · 2003 · 154 citations

Life Sciences, Immunology, Pharmacology +14